On June 8, 2026 BostonGene, developer of the leading AI model for tumor and immune biology, reported that six abstracts have been accepted for presentation at European Hematology Association (EHA) (Free EHA Whitepaper) 2026 Congress, taking place June 11 – 14 in Stockholm, Sweden. As Europe’s premier congress for hematology, the annual EHA (Free EHA Whitepaper) meeting brings together world-leading clinicians and researchers to share medical breakthroughs in the diagnosis, treatment, and clinical management of blood disorders.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentations showcase how BostonGene’s platforms integrate clinical, genomic, and immune data to uncover critical disease mechanisms. Conducted in collaboration with leading institutions, including Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, the University of Miami, and UT MD Anderson, this research demonstrates how integrated multiomics, predictive modeling, and high-dimensional blood immune system profiling can define resistance phenotypes to CAR-T therapies, identify unique immune states, and uncover deep remission pathways. These findings deliver actionable data that enable smarter patient selection, optimize frontline treatment decision-making, and enhance clinical trial design for blood cancers.

Details about the abstracts selected for presentation can be found below:

Oral presentation
Abstract: S283
Title: Integrated Multi-Omic Profiling Identifies Genomic Subtypes Associated with Differential Outcomes after CAR-T Therapy in Large B-Cell Lymphoma
Date & time: Saturday, June 13 | 18:00 – 18:15 CEST
Speaker: Silvia Escribano Serrat, MD, Memorial Sloan Kettering Cancer Center

Researchers at Memorial Sloan Kettering Cancer Center leveraged BostonGene’s multimodal computational pipeline, integrating molecular classifiers with gene signatures, to characterize mechanisms of CAR-T resistance in large B-cell lymphoma. Using the BostonGene Lymphly classifier, the BN2 subtype emerged as a high-risk group associated with significantly inferior survival and reduced response rates. Compared with existing frameworks, Lymphly provided improved stratification and clearer discrimination of outcome-relevant subgroups, underscoring the value of integrated molecular profiling for refining risk assessment following CAR-T.

Research conducted in collaboration with Memorial Sloan Kettering Cancer Center

Poster presentations

Abstract: PS2188
Title: Overlaying TP53 Loss and Aneuploidy with Distinct Diffuse Large B-Cell Lymphoma Subtypes Refines Tumor Classification and Enhances Risk Stratification
Date & time: Saturday, June 13 | 18:45 – 19:45 CEST
Speaker: Pavel Zemskiy, MS, BostonGene

BostonGene integrated two dimensions of genomic instability, TP53 loss‑of‑function alterations and quantitative aneuploidy, into Lymphly, a classification framework for diffuse large B‑cell lymphoma. This approach explicitly separates TP53 loss from aneuploidy, clarifying their independent and combined effects on tumor biology. By defining these mechanisms, the framework enables drug developers to anticipate and bypass resistance pathways, identify biomarker‑driven patient groups, and design trials aligned with genomic instability profiles.

Research conducted in collaboration with Center for Cancer Research

Abstract: PS1829
Title: Risk-Stratified Patient Selection in Multiple Myeloma for Frontline Treatment Decision-Making Based on a Transcriptomic Classifier
Date & time: Saturday, June 13 | 18:45 – 19:45 CEST
Speaker: Evgenia Alekseeva, PhD, BostonGene

BostonGene developed a transcriptomic-based risk stratification model to identify newly diagnosed multiple myeloma patients who may benefit from risk-adapted frontline treatment strategies, including aggressive regimens with bispecific T-cell engager (BiTE) and CAR T-cell therapies. This model outperformed conventional tools by isolating high-, intermediate-, and low-risk groups, while exposing high-risk cases with established resistance to proteasome inhibitors. Together, these findings define a biologically distinct high-risk state that may help prioritize patients for novel, more intensive treatment approaches earlier in the disease course.

Abstract: PS1854
Title: Peripheral Blood Immunoprofiling Defines Three Distinct Immune States Associated with Clinical and Molecular Axes in Multiple Myeloma
Date & time: Saturday, June 13 | 18:45 – 19:45 CEST
Speaker: Anastasia Radko, MS, BostonGene

BostonGene applied high‑dimensional flow cytometry to characterize peripheral blood immune architecture in multiple myeloma. Three coordinated immune states emerged, each aligned with cytogenetic risk, therapy exposure, and disease subtype. By defining these mechanisms, spanning T‑cell differentiation, checkpoint enrichment, and monocyte expansion, the framework enables drug developers to anticipate resistance, identify biomarker‑driven patient groups, and design trials that integrate circulating immune states into active therapeutic strategies.

Research conducted in collaboration with University of Miami

Abstract: PS2344
Title: Tazemetostat-Mediated Immune Remodeling in B-Cell Lymphomas Receiving CAR-T
Date & time: Saturday, June 13 | 18:45 – 19:45 CEST
Speaker: Samuel Yamshom, MD, Weill Cornell Medicine

BostonGene applied its multimodal molecular profiling platform to characterize the systemic immune remodeling driven by tazemetostat priming in patients with B-cell lymphomas receiving CART therapy. By integrating high-parameter flow cytometry, RNA sequencing, immune cell deconvolution, and functional gene signature analysis, BostonGene’s analysis revealed systemic immune remodeling associated with enhanced antigen presentation, T-cell activation, and reduced immunosuppressive signaling, validating the use of EZH2 inhibition for improved CART efficacy and durability.

Research conducted in collaboration with Weill Cornell Medicine

Abstract: PS1673
Title: Integrated Transcriptomic and Immune Profiling Identifies Determinants of Deep Remission with Ibrutinib–Venetoclax in Chronic Lymphocytic Leukemia
Date & time: Saturday, June 13 | 18:45 – 19:45 CEST
Speaker: Varsha Gandhi, PhD, UT MD Anderson

Leveraging BostonGene’s blood immunoprofiling platform and KassandraTM cell deconvolution, researchers at UT MD Anderson investigated the impact of ibrutinib–venetoclax combination therapy in patients with chronic lymphocytic leukemia. The findings revealed immune cell populations and gene expression patterns consistent with a common treatment resistance mechanism among patients who did not achieve remission. This study highlights BostonGene’s ability to harmonize clinical, genomic, transcriptomic, and immune data for reliable insights that drive smarter patient selection and optimized treatment decisions.

(Press release, BostonGene, JUN 8, 2026, View Source [SID1234666494])

On June 7, 2026 OriCell Therapeutics Holdings Limited ( The "Company" or "Oricell") , reported that its proprietary GPC3-targeted autologous CAR-T therapy, Ori-C101, has received clearance from China’s National Medical Products Administration (NMPA) to proceed into a confirmatory Phase II clinical trial in patients with GPC3-positive advanced hepatocellular carcinoma (HCC). The study is designed as a prospective, randomised, open-label, multi-centre registration trial evaluating the efficacy and safety of Ori-C101 in patients who have failed two or more prior lines of therapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This marks the first GPC3-directed immune cell therapy anywhere in the world to enter a confirmatory trial, and the first CAR-T product for a liver cancer indication to reach a Phase II randomised controlled study — a milestone that underscores China’s potential to lead the next wave of innovation in cell therapy for solid tumours.

HCC, a disease with few options at the late line

Hepatocellular carcinoma is among the most prevalent malignancies globally, with China alone accounting for roughly 410,000 new cases and 317,000 deaths each year. For patients whose disease has progressed through both immune checkpoint inhibitors (ICI) and tyrosine kinase inhibitors (TKI), options are essentially exhausted: existing second-line agents were developed for patients intolerant of, or progressing on, first-line sorafenib, and nothing has been approved beyond that point. The unmet need is acute.

Phase I data of Ori-C101: robust efficacy and manageable safety

Results from the Phase I BEACON study were featured as an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, which recently wrapped up in Chicago, drawing significant attention from the oncology community. All enrolled patients had failed at least two prior lines of therapy, including both TKI and ICI treatment.

Key results:

Objective response rate (ORR): 50% across the evaluable population; 66.7% in the recommended Phase II dose (RP2D) cohort; 100% in the highest dose cohort (DL4)

Speed of response: 89% of responders had already achieved objective response by their first post-infusion assessment, with marked tumour shrinkage

Overall survival (OS): Median OS of 21.4 months in the overall population; 12-month survival rate of 69.3% — more than double the roughly 10.6-month historical median seen with available second-line agents, heralding a potential new era of long-term survival for patients with advanced HCC

Safety: Cytokine release syndrome (CRS) was manageable; no immune effector cell-associated neurotoxicity syndrome (ICANS) or off-target toxicity was observed, and tolerability was favourable across the study population

Notable case: One patient achieved partial response at first assessment, progressed to complete response by month four, and remains in remission at 24 months

Mechanism and broader potential

GPC3 (Glypican-3) is overexpressed in more than 70% of hepatocellular carcinomas, as well as in gastric cancer, lung squamous cell carcinoma, and ovarian clear cell carcinoma — making it a highly specific and compelling target for cancer therapy. Ori-C101 is engineered to identify and eliminate GPC3-positive tumour cells with precision, drawing on two proprietary platforms: OriAb (AI-assisted antibody discovery and engineering) and OriArmoring (structure-enhanced cell platform).

Ori-C101’s profile has the potential to support use in earlier lines of treatment, and GPC3’s expression across multiple tumour types provides a strong scientific rationale for future indication expansion. As the confirmatory trial advances, the goal of treatment in advanced HCC has the potential to shift from controlling disease to achieving durable remission — or even cure.

Principal investigators

The confirmatory Phase II study is a nation-wide, multi-centre trial co-led by Professor Fan Jia (Academician of the Chinese Academy of Sciences and Honorary President of Zhongshan Hospital, Fudan University) and Professor Qin Shukui (Qiantang Scholar and Professor at Nanjing Tianyinshan Hospital, China Pharmaceutical University).

In a joint statement, the two investigators said: "In our earlier work on late-line advanced HCC, the BEACON study delivered important progress. GPC3 is specifically overexpressed in HCC and represents an ideal therapeutic target, yet GPC3-directed CAR-T approaches have historically been constrained by the immunosuppressive tumour microenvironment. BEACON was designed precisely to break through that barrier and find a new, accessible path for patients who have exhausted their options. The preliminary results from this novel ‘armoured’ GPC3 CAR-T construct — showing strong objective response rates with a manageable safety profile — not only address an evidence gap in late-line refractory HCC but offer broader lessons for innovative immune cell therapies in solid tumours. We look forward to the Phase II randomised controlled study, and to obtaining the expected results under rigorous scientific design, comprehensive management, and strict quality control."

OriCell co-founder, Chairman and Chief Executive Officer Dr. Yang Huanfeng commented: "We are deeply grateful to the NMPA Centre for Drug Evaluation and relevant government authorities for their strong support of innovative drug development, and to Academician Fan, Professor Qin and their teams for their trust and active participation. This approval validates the scientific soundness and feasibility of our technology platform and marks a new stage of growth for OriCell. With a clear regulatory pathway now in place, we will push forward with Ori-C101’s confirmatory clinical development, with the aim of bringing a genuinely new treatment option to patients as quickly as we can. We believe this progress will also underpin China’s strategy for taking innovative medicines global and competing actively in international markets."

(Press release, OriCell Therapeutics, JUN 7, 2026, View Source [SID1234666476])

On June 5, 2026 GlyTherix reported the grant of a Canadian patent covering its antibody-drug conjugate (ADC) technology, marking another important milestone in the expansion of the company’s global intellectual property portfolio.
The Canadian patent strengthens protection for GlyTherix’s proprietary ADC platform in a strategically important market and reinforces the company’s commitment to building a robust international patent estate around its innovative oncology programs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

With this latest grant, GlyTherix continues to advance the global protection of its technology, enhancing the long-term value of its ADC assets and supporting future development and partnering opportunities.

Strong intellectual property protection is a critical component of successful drug development, and the Canadian patent provides further validation of the novelty and potential of GlyTherix’s targeted cancer therapy approach.

The continued expansion of GlyTherix’s patent portfolio positions GlyTherix to maximise the impact and commercial potential of its technology for patients and stakeholders worldwide.

(Press release, Glytherix, JUN 5, 2026, View Source [SID1234666465])

On June 5, 2026 Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), reported results from an independent market landscape assessment evaluating Annamycin in relapsed/refractory acute myeloid leukemia (R/R AML).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The research demonstrated strong physician interest in Annamycin, with oncologists reporting an average likelihood-to-prescribe score of 6 out of 7. Physicians cited Annamycin’s reported complete remission rates, MRD-negative responses, potential to bridge patients to bone marrow transplant, biomarker-agnostic applicability and reduced cardiotoxicity as key factors supporting potential adoption.

The study included perspectives from academic and community hematologist-oncologists, medical oncologists and pediatric AML specialists. Respondents consistently identified significant unmet need in R/R AML, particularly for patients without actionable mutations and those who relapse or progress following venetoclax-based therapy. Separately, interviews with hospital administrators and insurers revealed that payers view Annamycin as a potentially meaningful value proposition, driven by its efficacy and safety profile and applicability to a broad patient population.

"These independent research findings are highly encouraging and reinforce the potential role we believe Annamycin can play in addressing one of the most difficult areas of AML treatment," said Walter Klemp, Chairman and Chief Executive Officer of Moleculin Biotech. "A physician likelihood to use score of 6 out of 7 reflects meaningful enthusiasm from clinicians who treat AML patients every day. Importantly, the research highlights that physicians recognize that Annamycin is capable of delivering powerful efficacy, producing deep remissions that position patients for transplant and serving a broader population beyond narrow biomarker-defined subsets. Physicians also recognized Annamycin’s safety profile, with the potential for repeat dosing due to the absence of cardiotoxicity."

Key Research Findings

The independent market assessment found that:

Hematologist-oncologists reported an average likelihood to prescribe Annamycin of 6 out of 7.
Physicians expressed strong interest in Annamycin’s reported complete remission and MRD-negative remission profile.
Respondents viewed Annamycin’s potential to bridge patients to bone marrow transplant as a meaningful clinical advantage.
Biomarker-agnostic applicability was viewed as highly relevant given the limitations of mutation-targeted therapies, and physicians noted the potential to combine targeted therapies with Annamycin.
Reduced cardiotoxicity was identified as an important differentiator, providing the possibility for repeat dosing, particularly given the known cardiac limitations of traditional anthracyclines.
Pediatric AML specialists viewed reduced cardiotoxicity as especially meaningful due to long-term survivorship concerns.
Payers indicated that Annamycin’s efficacy profile, safety characteristics and broad applicability could support a compelling value proposition.
Significant Unmet Need Remains in R/R AML

Despite recent progress in targeted therapies, respondents reported that the R/R AML treatment landscape remains fundamentally underserved. Physicians noted that targeted therapies have improved treatment for select biomarker-defined patient groups, but many patients still lack effective options, particularly following venetoclax failure or in the absence of actionable mutations.

Durable remission, improved survival and successful transition to potentially curative transplant were consistently identified as the most important treatment goals.

Annamycin Profile Resonates Across Stakeholders

Across respondent groups, Annamycin generated strong interest due to its reported efficacy profile and potential applicability across a broad R/R AML population. Physicians responded favorably to the combination of deep responses, transplant-enabling potential, broad use independent of mutation status and reduced cardiotoxicity.

The research also found that clinicians viewed Annamycin as a differentiated approach that may preserve the established anti-leukemic activity of the anthracycline class while reducing one of the class’s most significant historical limitations.

"We believe the findings provide important third-party validation of both the clinical and commercial potential of Annamycin," added Mr. Klemp. "As we continue advancing Annamycin, our focus remains on developing a therapy that may address meaningful unmet needs for AML patients, physicians and healthcare systems."

(Press release, Moleculin, JUN 5, 2026, View Source [SID1234666466])

On June 5, 2026 Nerviano Medical Sciences S.r.l. ("NMS"), a global oncology-focused biopharmaceutical company, reported its participation in the upcoming Annual Congress of the European Association for Cancer Research (EACR), taking place in Budapest, Hungary, from June 8 to 11, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At the meeting, NMS will present a scientific poster featuring its proprietary dual PERK/GCN2 inhibitor, NMS-812.

Title: "NMS-812, a clinical stage dual PERK and GCN2 modulator, with activity in Multiple Myeloma, AML and solid tumors" (Poster EACR26-0678)

Presenter: Claudia Perrera, Head of Biology at NMS

Poster Section: "Experimental / Molecular Therapeutics, Pharmacogenomics"

Poster Board Number: P-355

Date & Time: Tuesday, 09 June 2026 from 10:30 to 20:00 CET

Link to full poster abstract: NMS POSTER SESSION – Tuesday – EACR Congress

This study presents NMS-812, a potent first-in-class clinical-stage dual PERK/GCN2 inhibitor that disrupts tumor stress-response survival pathways, demonstrating single-agent and combination antitumor activity across multiple myeloma, AML, and solid tumor models, including immune-mediated effects, supporting its ongoing Phase 1 AML development and potential expansion into solid tumors.

We look forward to engaging with the scientific community at EACR 2026 and sharing insights from our work.

(Press release, Nerviano Medical Sciences, JUN 5, 2026, View Source [SID1234666467])